The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
Open accessAbstract
Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hypothesis that high levels of mutational heterogeneity in the tumor could be the key for the success of immune checkpoint-targeting therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“…% Prostate 0,73 0% (0/13) NSCLC never smoker 0,6 10% (1/10) References Lawrence et al. 2013 Govindan et al. 2012 topalian et al. 2012 Hamid et al. 2013 Brahmer et al. 2012 Hamid et al. 2013 Soria et al. 2013 Cho et al. 2013 Chen et al. 2012 www.landesbioscience.com OncoImmunology e27817-3 for…”
BackgroundVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 1×
“com OncoImmunology e27817-3 for various solid tumors.(9,10,11) Somatic mutations may be the consequence of defective DNA repair, the infidelity of the DNA replication machinery or the exposure to mutagens.”
BackgroundMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798 · cited 1×
“The exomeguided immunomonitoring of patients treated with checkpoint-targeting agents has recently revealed that tumors are producing a large panel of neo-antigens that can drive immune responses.(15) These neo-antigens originate from the so-called tumor “mutanome,” the ensemble of tumor-specific (and hence most often…”
BackgroundHadrup, S. R., Bakker, A. H., Shu, C. J., Andersen, R. S., van Veluw, J., Hombrink, P., Castermans, E., thor Straten, P., Blank, C., Haanen, J. B., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1345 · Cited by 306
Cited by
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Current and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. D., Lewis, V. O., & Gorlick, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 689
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Gettinger, S., Rizvi, N. A., Chow, L. Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D. E., Shepherd, F. A., Antonia, S., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9929 · Cited by 501
Immunotherapy for pancreatic cancer: A 2020 update
Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., Ziogas, D., Psyrri, A., & Karamouzis, M. V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102016 · Cited by 458
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S., Chow, L. Q., Gerber, D. E., Laurie, S. A., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9861 · Cited by 445
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4697-y · Cited by 439
Hodges, T. R., Ott, M., Xiu, J., Gatalica, Z., Swensen, J., Zhou, S., Huse, J. T., de Groot, J., Li, S., Overwijk, W. W., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox026 · Cited by 404
Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400
Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment
Marzagalli, M., Ebelt, N. D., & Manuel, E. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.002 · Cited by 345
Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., & O’Rourke, D. M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy032 · Cited by 312
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Gabrielson, A., Wu, Y., Wang, H., Jiang, J., Kallakury, B., Gatalica, Z., Reddy, S., Kleiner, D., Fishbein, T., Johnson, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0110 · Cited by 299
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 275
Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27303-7 · Cited by 175
Koirala, P., Roth, M. E., Gill, J., Chinai, J. M., Ewart, M. R., Piperdi, S., Geller, D. S., Hoang, B. H., Fatakhova, Y. V., Ghorpade, M., et al. (2016) · Scientific Reports · doi:10.1038/srep31154 · Cited by 100
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, M., Indraccolo, S., Zagonel, V., & Lombardi, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.12.002 · Cited by 87
Balatoni, T., Mohos, A., Papp, E., Sebestyén, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., Gaudi, I., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2072-1 · Cited by 76
Metadata
- Authors
- Champiat, S., Ferté, C., Lebel-Binay, S., Eggermont, A., & Soria, J. C.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2014-01
- Volume
- 3
- Issue
- 1
- Pages
- e27817
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W1990189227
- Cited by
- 192
- References
- 7
- FWCI
- 14.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.